Ovarian CancerNCT01268956
Circulating Lymphatic Progenitor Cell and Lymph Node Metastasis
An observational study of Ovarian Cancer, run by Hospital Universitari de Bellvitge at 1 site in China.
Trial summary
Correlation of circulating lymphatic endothelial progenitor cells with lymph node metastasis Read more about this study
- Who is it for?
- Ages 15 to 80 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Ovarian Cancer
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- Jan 2011to Sep 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 80 years
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: ovarian cancer patients
Who may be able to join
- ovarian cancer patients diagnosed by pathologic examination
Who cannot join
- other malignant disease inflammatory disease untreated diabetic and hypertension chronic renal failure rheumatoid arthritis
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Obstetrics & Gynecology, Southwest Hospital
Chongqing, Sichuan, 400038
About this study
Official title: Correlation of Circulating Lymphatic Progenitor Cells With Lymph Node Metastasis in Ovarian Cancer Patients
Correlation of circulating lymphatic endothelial progenitor cells with lymph node metastasis
Read the detailed description
Correlation of circulating lymphatic endothelial progenitor cells with lymph node metastasis in ovarian cancer patients
- Conditions
- Ovarian Cancer
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Lymphatic progenitor cell | Circulating lymphatic progenitor cell | |
| Control | healthy people |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jan 2011 (estimated)
- Study startJan 2011
- Primary completionJun 2011 (estimated)
- Study completionSep 2011 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Universitari de Bellvitge
- Sponsor type
- University, hospital or other
- Investigators
- Pianyifan pianyifan, Doctor, Principal investigator, Southwest Hospital, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01268956
- Sponsor's protocol ID
- 20101231001
- Status last verified
- Dec 2010
- First submitted
- 3 Jan 2011
- Last updated
- 4 Jan 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jan 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation of Circulating Lymphatic Progenitor Cells With Lymph Node Metastasis in Ovarian Cancer Patients
- ClinicalTrials.gov ID
- NCT01268956
- Acronym / sponsor ID
- 20101231001
- Conditions
- Ovarian Cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Hospital Universitari de BellvitgeUniversity, hospital or other
- Study start
- Jan 2011
- Primary completion
- Jun 2011 (estimated)
- Study completion
- Sep 2011 (estimated)
- First posted
- 4 Jan 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Correlation of circulating lymphatic endothelial progenitor cells with lymph node metastasis
Detailed description
Correlation of circulating lymphatic endothelial progenitor cells with lymph node metastasis in ovarian cancer patients
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lymphatic progenitor cell | – | –Circulating lymphatic progenitor cell |
| Control | – | –healthy people |
Who may qualify
- Ages
- 15 to 80 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- ovarian cancer patients
Key inclusion criteria (1 listed)
- ovarian cancer patients diagnosed by pathologic examination
Key exclusion criteria (1 listed)
- other malignant disease inflammatory disease untreated diabetic and hypertension chronic renal failure rheumatoid arthritis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jan 2011.
Related trials for Ovarian Cancer
Active, not recruitingPhase 2
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Ovary Cancer, Fallopian Tube Cancer
Recruiting
Methylation Profiling in Self-samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingObservational study
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Cancer, Cancer Diagnosis
RecruitingPhase 3
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody)
RecruitingPhase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pianyifan pianyifan, Doctor principal investigator
Southwest Hospital, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ovarian Cancer, run by Hospital Universitari de Bellvitge at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Jan 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Huiling Qiu Zhiqing Liang, Doctor (86-23-68754813, zhi.lzliang@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2011.